12 completed, 2 recruiting, 2 unknown. 11 Not applicable, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 8, Recruiting 2, Unknown 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
Follow GIP: new trials by email Literature Review of GIP trials Research Report on GIP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion GIP, GLP-1, Saline (0.9% Sodium Chloride) - Type 2 Diabetes, Healhty | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 36 | 2026-03-12 | 2026-10-27 |
| The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals Placebo (saline), GIP, Alanine - Effect of iv Administration of GIP and Alanine | Phase 1 | Unknown | University Hospital, Gentofte, Copenhagen | 10 | 2024-01-01 | 2024-05-17 |
| Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury Meal test, GIP, GLP-2 - Spinal Cord Injuries | Not applicable | Unknown | University of Copenhagen | 20 | 2021-11-16 | 2023-05-10 |
| The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes GIP - Diabetes Mellitus, Type 1, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 20 | 2019-06-01 | 2020-01-27 |
| Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19 GLP-2, GIP, Placebo - Type 2 Diabetes Mellitus | Not applicable | Completed | University of Copenhagen | 10 | 2019-02-26 | 2020-11-04 |
| Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism. Liquid meal (Nutridrink), GIP, GLP-2 - Hypoparathyroidism | Not applicable | Completed | University of Copenhagen | 7 | 2018-09-12 | 2019-12-12 |
| Gut Hormones and Bone Remodeling in Humans (KS-2) GLP-2, GIP, GLP-2+GIP - Healthy | Not applicable | Completed | University of Copenhagen | 10 | 2017-09-15 | 2020-01-18 |
| Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle GLP-1, Insulin Actrapid, Oral amino acids - Sarcopenia | Not applicable | Completed | University of Nottingham | 40 | 2014-11-01 | 2018-05-02 |
| Beta-cell Response to Incretin Hormones in Cystic Fibrosis GLP-1, GIP - Cystic Fibrosis, Pancreatic Insufficiency | Not applicable | Recruiting | University of Pennsylvania | 45 | 2013-05-01 | 2026-01-14 |
| Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes GIP, GLP-1, Saline - Type 1 Diabetes Mellitus | Not applicable | Completed | Mikkel Christensen | 10 | 2012-11-17 | 2017-06-23 |
| Hyperglycemia and the Extra-pancreatic Effect of Incretins Saline, GIP, GLP-1 - Extra-pancreatic Incretin Effect, Glucose Effectiveness | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 20 | 2012-09-01 | 2014-12-03 |
| GIP and GLP-1 in Type 1 Diabetes GIP, GLP-1, Saline - Hypoglycemia | Not applicable | Completed | Mikkel Christensen | 10 | 2012-07-01 | 2015-07-13 |
| Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Washington University School of Medicine | 38 | 2009-10-01 | 2014-07-22 |
| Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Diabetes | Phase 1 | Completed | Washington University School of Medicine | 40 | 2008-12-01 | 2018-05-03 |
| GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Glucose-insulinotropic peptide, Glucagon-like peptide-1 - Physiology, Gastroenterology | Phase 1 | Completed | Uppsala University | 15 | 2006-08-01 | 2010-03-03 |
| GIP: Glucose-dependent Insulinotropic Peptide GIP, Modified GIP, Normal Saline - Type 2 Diabetes | Phase 1 | Completed | National Institute on Aging (NIA) | 41 | 2003-02-01 | 2013-11-28 |
Diabetes Mellitus, Type 2 (4) · Bone Resorption (3) · Diabetes Mellitus (3) · Insulin Resistance (3) · Diabetes Mellitus, Type 1 (2) · Hypoglycemia (2) · Cystic Fibrosis (1) · Endocrine System Diseases (1) · Exocrine Pancreatic Insufficiency (1) · Glucose Metabolism Disorders (1) · Hypoparathyroidism (1) · Metabolic Diseases (1) · Sarcopenia (1) · Spinal Cord Injuries (1) · Xanthomatosis, Cerebrotendinous (1)
University of Copenhagen (4) · Copenhagen University Hospital, Rigshospitalet (2) · Mikkel Christensen (2) · Washington University School of Medicine (2) · National Institute on Aging (NIA) (1) · Steno Diabetes Center Copenhagen (1) · University Hospital, Gentofte, Copenhagen (1) · University of Nottingham (1) · University of Pennsylvania (1) · Uppsala University (1)
Denmark (9) · United States (4) · Sweden (1) · United Kingdom (1)
Burton Wice, PhD (2) · Dominic Reeds, MD (2) · Mette Rosenkilde, MD (2) · Filip K Knop, MD, PhD (1) · Iskandar Idris, DM, FRCP (1) · Josephine Egan, MD (1) · Mette M Rosenkilde, Prof., MD (1) · Michael R. Rickels, MD, MS (1) · Mikkel Christensen, MD (1) · Per M Hellstrom, MD, PhD (1) · Philip Atherton, PhD (1) · Thomas PJ Solomon, PhD (1)
PMID 22522617, PMID 24183983, PMID 24356886, PMID 24712564, PMID 25053587, PMID 29099978, PMID 34405256, PMID 35111398, PMID 35796669, PMID 36111559, PMID 36260533, PMID 40004948
1RC1DK086163-01 (1), R01DK088126 (1)